Characteristics of Skin Lesions Associated with Anti-Tumor Necrosis Factor Therapy
As noted in previous blog posts (see below), anti-tumor necrosis factor (anti-TNF) therapy has been associated with skin problems. The following study/abstract elaborate on this issue further and indicate that while ~30% of patients with IBD may develop skin reactions, only 28 of 917 (3%) patients required anti-TNF therapy to be discontinued due to skin reactions.
I Cleynen et al. Ann Intern Med. Published online 8 December 2015 doi:10.7326/M15-0729 Characteristics of Skin Lesions Associated With Anti–Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease: A Cohort Study ONLINE FIRST
Objective: To describe patients treated with anti-TNF antibodies who did and did not develop skin lesions.
Design: Retrospective cohort.
Setting: Single IBD tertiary referral center.
Patients: 917 consecutive patients with IBD who initiated anti-TNF therapy.
Measurements: Skin lesions, patient demographic characteristics, treatments, clinical course, and serologic and genetic markers.
Results: During a median follow-up of 3.5 years (interquartile range [IQR], 0.5 to 7.4 years), skin lesions associated with the use of anti-TNF therapy developed in 264 of 917 (29%) patients (psoriasiform eczema, 30.6%; eczema, 23.5%; xerosis cutis, 10.6%; palmoplantar pustulosis, 5.3%; psoriasis, 3.8%; other, 26.1%). Lesions typically developed at flexural regions, genitalia, and the scalp, especially the psoriasiform lesions. Thirty-one percent of women and 26% of men developed lesions. Median cumulative doses (2864 mg/y [IQR, 2203 to 3819 mg/y] and 2927 mg/y [IQR, 2377 to 3667 mg/y]) and trough levels (4.2 µg/mL [IQR, 2.6 to 5.8 µg/mL] and 4.0 µg/mL [IQR, 1.6 to 5.9 µg/mL]) of infliximab were similar in patients with and without lesions. All but 28 patients (11%) were successfully managed without needing to stop therapy because of lesions.
Limitation: Retrospective nature and no matched control group of patients not receiving anti-TNF therapy.
Conclusion: Skin lesions occur frequently in association with anti-TNF therapy but rarely require discontinuation of therapy. Close surveillance and early referral to a dedicated dermatologist are recommended.
Related blog posts:
Sleep Duration and Subsequent Obesity
A provocative study from Brazil (CSE Halal et al. J Pediatr 2016; 168: 99-103) examined a cohort of 4231 infants and assessed sleep duration from 1-4 years of age.
Findings:
- 10.1% of cohort had short sleep duration at any follow-up
- At 4 years of age, 201 children (5.3%) were obese and 302 (8%) were overweight
- Prevalence ratio for obesity/overweight was 1.32 among those who were ‘short-sleepers’
This study introduction notes that studies in adults have suggested an association between poor sleep and weight gain, “possibly through elevation of cortisol and gherlin levels, along with reduction in leptin levels, thereby leading to increased hunger and reduced energy expenditure.”
Normal sleep patterns: for infants 12-15 hours/day, & for toddlers 11-14 hours/day. At night, average expected sleep is 12 hours at 1 year of age and 11 hours at 4 years of age.
My take: Looking at early sleep patterns helps reduce the likelihood of reverse causation. This study and others shows an association with less sleep and increased likelihood of weight gain. Why???
In same issue (AI Wijtzes et al. J Pediatr 2016; 168: 118-25) report that breakfast skipping at age 4 years is associated (ß =1.38) with a higher percent fat mass at age 6 years, though no associations were found with BMI or weight status. This study involved prospectively collected data from 5914 children in the “Generation R Study” in The Netherlands.
Briefly noted: JA Emond et al. J Pediatr 2016; 168: 158-63. “Greater child commercial TV viewing was significantly associated with more frequent family visits to those fast food restaurants …toy collecting partially mediated that positive association.” This study involved 100 parents with children aged 3-7 in a rural community.
Related blog posts:
Adolescent Bariatric Surgery Outcomes at 3 Years
A prospective study (TH Inge et al. NEJM 2016; 374: 113-23) with 242 adolescents from five U.S. centers provides data on outcomes at 3 years. Here’s the scoop:
- At baseline, mean age was 17 years, 75% were female, 72% were white, and mean BMI was 53.
At 3 years:
- Mean weight decreased 27% (similar results for gastric bypass and gastric sleeve)
- 95% had remission of type 2 diabetes (of those with diabetes at baseline)
- 86% had remission in abnormal kidney function (of those with diabetes at baseline)
- 74% had remission in elevated blood pressure (of those with diabetes at baseline)
Table 4 details the serious complications:
- 13% of the participants (n=30, 47 procedures) had undergone additional abdominal procedures. While most of these were related to the procedure, a good number may have occurred regardlessly (eg. 18 cholecystectomies, 2 appendectomies)
- 13% (n=29) also underwent endoscopic procedures including 9 who needed stricture dilatation.
The most common nutrient deficiency at followup was iron deficiency. 57% had low ferritin levels at 3 years compared with 5% at baseline. Vitamin B12 deficiency was common; it declined by 35% and 8% had a deficiency at 3 years. Vitamin A deficiencies increased (16% at 3 years). My take: this study documents the durability of weight loss and its beneficial effects on a multitude of problems. It also shows that careful followup is needed for nutrient deficiencies and the risks of adverse events. Related blog posts:
- Is a Three Year-Old Too Young for Bariatric Surgery …
- Reaching Consensus on Bariatric Intervention… | gutsandgrowth
- Trends in Adolescent Bariatric Surgery | gutsandgrowth
- Six year outcomes with bariatric surgery | gutsandgrowth
- Staggering cost of obesity | gutsandgrowth
- Two new drugs for obesity | gutsandgrowth
- Treating diabetes with surgery | gutsandgrowth
- Six years later-Mediterranean diet comes out on top | gutsandgrowth
- Childhood Obesity and Consensus Recommendations | gutsandgrowt
- Have you seen the Duodenal-Jejunal Bypass Liner? | gutsandgrowth
Proton Pump Inhibitors Webinar
For those who missed the live NASPGHAN webinar, it is also available on demand: Link: Proton Pump Inhibitors Webinar. CME credit is available too.
Overall, this is a terrific review and intended for a high level audience. Here are a couple of key points from the talk:
- Dr. Jennifer Lightdale introduced the webinar. She noted that there has been a tremendous rise in the use of proton pump inhibitors (PPIs) in children over the past 15 years, including in infants.
- Preponderance of evidence does not support use of PPIs for reducing GER symptoms or crying in infants.
- PPIs are extremely effective at acid suppression.
- Excellent discussion by Dr. Rachel Rosen on Nonerosive Reflux Disease (NERD) and distinguishing this entity from erosive reflux disease, hypersensitive esophagus, and functional heartburn.
- On a microscopic level, NERD is similar to erosive reflux with microscopic inflammation and dilated intracellular spaces.
- With regard to testing, it is recommended that for impedance studies, that acid suppression be stopped prior due to improved sensitivity/accuracy.
- For those at odds with their pulmonologists and ENT colleagues, Dr. Ben Gold reviewed the literature on asthma, cough, and laryngeal-pharyngeal pathology related to reflux. The sensitivity of laryngoscopic findings to identify reflux is poor. “There is insufficient evidence to recommend for OR against the use of acid suppression therapy.”
- Dr. Jose Garza reviewed the indications for PPI use which include eosinophilic esophagitis/PPI-REE, erosive esophagitis, NSAID prophylaxis, Upper GI bleeding, and H pylori therapy.
- Dr. Carlo DiLorenzo provided an in-depth discussion of the potential risks of PPI therapy and explained some of the context as well as absolute risks. He noted that besides the risk of infection, particularly C difficile, other risks demonstrated in adults have not yet been confirmed in children.
- “Prolonged acid suppression should be used only when indicated.” Thus, management should include strategies for treatment discontinuation in the majority of those receiving PPI therapy.
Related blog posts:
- The prosecution rests…PPIs on trial gutsandgrowth
- PPI Side Effects: “Dissecting the Evidence” | gutsandgrowth
- Treating reflux does not help asthma | gutsandgrowth
- Do medicines work for GERD infants? | gutsandgrowth
- Failure of PPI test | gutsandgrowth
- One for the PPI team | gutsandgrowth
- No Effect of Proton Pump Inhibitors and Irritability… | gutsandgrowth
Turning Conventional Colonoscopy Positioning Upside Down
A recent article (The American Journal of Gastroenterology 110, 1576-1581 (November 2015) | doi:10.1038/ajg.2015.298) indicates that right-sided positioning rather than left-side down results in quicker and more comfortable colonoscopy. While it is disconcerting to realize that I had been trained exactly opposite, if this technique works for me, it will be particularly helpful when patients undergo combination procedures since this means that the bed would not need to be rotated. Thanks to Mike Hart for this reference.
Right Or Left in COLonoscopy (ROLCOL)? A Randomized Controlled Trial of Right- versus Left-Sided Starting Position in Colonoscopy
N Vergis, A K McGrath, C H Stoddart and Jonathan M Hoare
Abstract
OBJECTIVES:
Colonoscopy is technically challenging and can cause discomfort for patients. We aimed to test whether right-sided starting position for colonoscopy would result in shorter procedure time and greater patient comfort when compared with conventional left-sided starting position.
METHODS:
We conducted a randomized controlled trial in which patients were randomized to begin in either the right- (RL) or conventional left-lateral (LL) position. One hundred and sixty-three adult patients undergoing scheduled colonoscopy were stratified by age, gender, body mass index, and experience of the endoscopist. Patients were then randomized 1:1 in permuted blocks. The primary outcome measure was time to cecal intubation and secondary outcome measures included patient comfort that was evaluated by visual analog comfort scale.
RESULTS:
Median time to reach the cecum was quicker when colonoscopy began with patients positioned RL rather than LL (P=0.0078). Moreover, patients found RL more comfortable than LL (P=0.02). Multiple linear regression confirmed starting position in colonoscopy as an independent determinant of time to reach the cecum (P=0.007). Women and those who had previously undergone abdominal surgery gained the greatest benefit from right-sided positioning (RL vs. LL: 498 vs. 824 s; P=0.03 and 498 vs. 797 s; P=0.006, respectively).
CONCLUSIONS:
Our study reveals that right-sided positioning at the start of colonoscopy results in more comfortable and quicker procedures. Of the factors identified by multiple linear regression to independently have an impact on time to reach the cecum, only starting position is modifiable. Right-sided starting position may therefore be of benefit in colonoscopy, in particular for women and patients who have previously undergone abdominal surgery.
Nummular Eczema due to Infliximab
An image report (YM Dawkins et al. Clin Gastroenterol Hepatolo 2016; 14: xxxv-xxxvi) describes a 30-year-old with ulcerative colitis who developed nummular eczema two years after the start of infliximab. He was treated with topical agents and a course of systemic corticosteroids. The authors note that in a few patients, withdrawal of anti-TNF therapy is needed, but this was not needed in their patient.
Related blog posts:
Increasing Rates of Abdominal Wall Birth Defect (Gastroschisis)
From NY Times summary of recent study, “Rate of Birth Defect of Abdominal Wall Increasing, CDC Says“:
The prevalence of gastroschisis has increased by about 30 percent, to 4.9 births out of 10,000 during the period from 2006 to 2012, from 3.6 per 10,000 live births from 1995 to 2005, according to the Centers for Disease Control and Prevention.
My take: This epidemiology is definitely concerning. Though most children with gastroschisis do well over time, some have serious problems and many require prolonged hospitalizations after birth.
Weight Gain in Preemies, Neurodevelopmental Outcomes, and Reverse Causation
Since a trial which randomizes premature infants into groups that are well-nourished and poorly-nourished and then following them prospectively is never going to happen, it is difficult to know with certainty the effects of optimal nutrition are with respect to long-term neurodevelopmental outcomes.
An article I enjoyed reading on this subject (MB Belfort et al. J Pediatr 2016; 168: 30-5) pushes back on the correlation between good weight gain, as a surrogate marker for nutritional status, and neurodevelopmental outcomes.
In this study, 1070 infants between 23-27 weeks gestational age were followed with weights on days 7-28 along with weights at 12 and 24 months. This data was compared with several indices on neurodevelopmental outcome. Here is the key finding: “Weight gain in the lowest quartile from 7-28 days was not associated with higher risk of adverse outcomes.”
In commentary on their findings, the authors point out that “we found no evidence to suggest that faster weight gain from 7 to 28 days of life reduced the risk of adverse outcomes…almost all of the associations between low weight gain..were attenuated or eliminated when we restricted our analysis to those children able to walk independently.”
“Overall, it appears that low weight in children with severe neurodevelopmental impairments may be caused by factors closely related to the impairments themselves…reverse causation may be at play.” Thus, underlying brain damage may limit body weight gain, rather than poor nutrition limiting brain development.”
My take: I may be apt to ‘confirmational bias’ as this study reinforces my view that improved nutrition may not change outcomes appreciably. To be clear, I still believe that efforts to optimize the nutrition of premature infants are a good idea but we need to be skeptical about the magnitude of benefit that we will derive.
Related blog posts:
Living Liver Donors: 97% Would Do It Again
A recent study (VR Humphreville et al. Liver Transpl 2016; 22: 53-62) indicates that living liver donors report a high satisfaction following donation.
The authors examined a cohort of 127 living liver donors from the University of Minnesota; donation had occurred between 2 years and 16 years previously. In addition to a donor-specific survey (DSS) completed by 107, the participants completed the short-form 36 health survey to assess health-related quality of life.
Key findings:
- Almost all donors reported that they would donate again (97.2%)
- Satisfaction rate correlated with the outcome of the liver transplant recipient along with pain after donation and vitality after donation. 91.6% rated their satisfaction with the donation process as >8 on a 10 -point scale, with 10 being “extremely satisfied”
- Health-related quality of life was higher among donors than the general population (though they likely had higher scores than the general population at baseline)
The study elaborates on the potential complications with the most frequent being incisional discomfort in 34%.
My Take: this information on high satisfaction will be useful for transplant programs and those considering living liver donation.




